The Oncology Institute, Inc. (STLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, The Oncology Institute, Inc. (STLN) has a cash flow conversion efficiency ratio of -0.479x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($11.94 Million) by net assets ($-24.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review The Oncology Institute, Inc. free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
The Oncology Institute, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how The Oncology Institute, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see STLN market cap overview for the company's overall valuation and market capitalisation.
The Oncology Institute, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of The Oncology Institute, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Properties & Resources Development Group Ltd
SHE:000011
|
-0.709x |
|
Innova Captab Limited
NSE:INNOVACAP
|
0.027x |
|
Skipper Limited
NSE:SKIPPER
|
0.092x |
|
Guangdong Super Telecom
SHG:603322
|
0.053x |
|
Bestlink Tech Co Ltd
SHG:603206
|
-0.067x |
|
Forward Air Corporation
NASDAQ:FWRD
|
0.040x |
|
CoinShares PLC Ordinary Shares
NASDAQ:CSHR
|
-0.001x |
|
ESGL Holdings Limited
NASDAQ:OIO
|
-0.041x |
Annual Cash Flow Conversion Efficiency for The Oncology Institute, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of The Oncology Institute, Inc. from 2022 to 2025. View STLN stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-15.72 Million | $-24.59 Million | 1.564x | +121.15% |
| 2024-12-31 | $3.59 Million | $-26.54 Million | -7.394x | -1061.11% |
| 2023-12-31 | $57.02 Million | $-36.31 Million | -0.637x | -27.02% |
| 2022-12-31 | $123.17 Million | $-61.76 Million | -0.501x | -- |
About The Oncology Institute, Inc.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educatio… Read more